Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

<p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p>

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Stephanie Lheureux (16797697) (author)
Eará dahkkit:	Stephenie D. Prokopec (16797700) (author), Leslie E. Oldfield (16797703) (author), Eduardo Gonzalez-Ochoa (16375918) (author), Jeffrey P. Bruce (16797706) (author), Derek Wong (15135437) (author), Arnavaz Danesh (15135449) (author), Dax Torti (15135467) (author), Jonathan Torchia (16797709) (author), Alexander Fortuna (16797712) (author), Sharanjit Singh (16797715) (author), Matthew Irving (16797718) (author), Kayla Marsh (15135470) (author), Bernard Lam (15051558) (author), Vanessa Speers (16797721) (author), Aleksandra Yosifova (16797724) (author), Ana Oaknin (14956029) (author), Ainhoa Madariaga (15129719) (author), Neesha C. Dhani (16797727) (author), Valerie Bowering (16797730) (author), Amit M. Oza (15129737) (author), Trevor J. Pugh (14940894) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Methods and Technology Computational Methods Sequence analysis Gynecological Cancers Ovarian cancer Liquid Biopsy
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid